Tech firm warns poorly made questionnaires can cause patient disengagement
The burden of questionnaires and never-ending documentation may be holding back successful trials and driving patients away, a tech firm …
Post
-
-
Supply chains too often “last cog” implemented in clinical trials
Placing emphasis on supply chains before initiating a clinical trial can help create protocols that are robust against delays, unlike …
-
BioAge halts ongoing Phase II trial of obesity drug due to liver concerns
BioAge Labs has halted the Phase II randomised STRIDES trial of its investigational drug azelaprag, both as single agent and …
-
Sanofi’s Phase III trial of rilzabrutinib for thrombocytopenia meets endpoint
Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune …
-
ASH 2024: AstraZeneca set to take a BiTE out of follicular lymphoma market
At the 2024 annual meeting of the American Society of Hematology (ASH), held on 7 December in San Diego, California, …
-
Novartis reports topline outcomes from Phase IIIB PNH trial of Fabhalta
Novartis has reported positive topline outcomes from the multicentre Phase IIIB APPULSE-PNH trial of oral Fabhalta (iptacopan) for treating adults …
-
Half of pharma and biotech companies using AI and big data
A survey conducted by ICON has found sentiment towards artificial intelligence (AI) and digital tools in the clinical research sector …
-
BioArctic doses first subject in Parkinson’s disease therapy trial
BioArctic has dosed the first subject with the monoclonal antibody, exidavnemab, in the randomised Phase IIa EXIdavnemab Synucleinopathy Trial (EXIST) …
-
Ryvu Therapeutics doses first subject in Phase II myelofibrosis treatment trial
Ryvu Therapeutics has initiated the Phase II trial, POTAMI-61, dosing the first subject with a small-molecule cyclin-dependent kinase (CDK) 8/19 …
-
Centenarians – unlocking the secrets of living to 100
The concept of extremely long life, popularised in films like Highlander, may seem like pure fiction, however; researchers are actively …
-
Nuvig secures $161m financing to support clinical studies for NVG-2089
Nuvig Therapeutics has closed a $161m Series B financing round to advance its preclinical pipeline and support NVG-2089’s clinical proof-of-concept …
-
“Systematic reviews” for underrepresented groups in trials needed, says WHO senior adviser
Systematic reviews are needed to address gaps in population representation in clinical trials to ensure the quality level of evidence …
-
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers
Merus’ Bizengri (zenocutuzumab-zbco) has received accelerated approval from the US Food and Drug Administration (FDA), marking “an important milestone” in …
-
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers
Merus’ Bizengri (zenocutuzumab-zbco) has received accelerated approval from the US Food and Drug Administration (FDA), marking “an important milestone” in …
-
Cidara achieves full enrolment in influenza prevention trial
Cidara Therapeutics has achieved full planned subject enrolment for the randomised Phase IIb NAVIGATE trial designed to assess the safety …
